Genetic component of complications in type 2 diabetes

Details for Australian Patent Application No. 2009259024 (hide)

Owner Prognomix, Inc.

Inventors Seda, Ondrej; Tremblay, Johanne; Hamet, Pavel; Macmahon, Stephen; Chalmers, John

Agent Davies Collison Cave

Pub. Number AU-A-2009259024

PCT Pub. Number WO2009/150550

Priority 61/061,389 13.06.08 US

Filing date 15 June 2009

Wipo publication date 17 December 2009

International Classifications

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

Event Publications

27 January 2011 PCT application entered the National Phase

  PCT publication WO2009/150550 Priority application(s): WO2009/150550

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009259026-Tricyclic 2,4-diamin0-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders

2009259021-2-pyridyl substituted imidazoles as ALK4 and/or ALK4 inhibitors